Jin‐Hee Ahn
About
Jin‐Hee Ahn is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Jin‐Hee Ahn has authored 29 papers receiving a total of 718 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 9 papers in Cancer Research and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jin‐Hee Ahn's work include Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Jin‐Hee Ahn is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Jin‐Hee Ahn collaborates with scholars based in South Korea, France and Poland. Jin‐Hee Ahn's co-authors include Hee Jin Lee, Gyungyub Gong, In Ah Park, In Hye Song, Jong Han Yu, Sei Hyun Ahn, Jin Young Seo, Joo Young Kim, Seock‐Ah Im and Marek Z. Wojtukiewicz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
Jin‐Hee Ahn
27 papers receiving 709 citations
Peers
Jin‐Hee Ahn
Shan Xiong China
Ioannis Zerdes Sweden
Frédérique Penault‐Llorca France
Marye J. Boers‐Sonderen Netherlands
Tomasz Sarosiek Poland
William Waterfield United States
Seyran Yiğit Türkiye
Dalin Li China
Rita Ruijter Netherlands
Citations per year, relative to Jin‐Hee Ahn Jin‐Hee Ahn (= 1×)
peers
Shan Xiong
Countries citing papers authored by Jin‐Hee Ahn
Since
Specialization
Citations
This map shows the geographic impact of Jin‐Hee Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin‐Hee Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin‐Hee Ahn more than expected).
Fields of papers citing papers by Jin‐Hee Ahn
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jin‐Hee Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin‐Hee Ahn. The network helps show where Jin‐Hee Ahn may publish in the future.
Co-authorship network of co-authors of Jin‐Hee Ahn
This figure shows the co-authorship network connecting the top 25 collaborators of Jin‐Hee Ahn. A scholar is included among the top collaborators of Jin‐Hee Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin‐Hee Ahn. Jin‐Hee Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jeong, Hyehyun, Jae Ho Jeong, Sangwon Han, et al.. (2025). Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors. European Journal of Nuclear Medicine and Molecular Imaging. 52(6). 2096–2106.
2.
Hyung, Jaewon, Sangwon Han, Jae Ho Jeong, et al.. (2024). Impact of18F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer. Journal of Nuclear Medicine. 65(11). 1689–1694.
3.
Kim, Yu Jung, Koung Jin Suh, Se Hyun Kim, et al.. (2024). Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second‐line treatment (EAGLES, Korean Cancer Study Group UN18‐06). Cancer. 131(1). e35609–e35609.
4.
Pivot, Xavier, Javier Cortés, Diana Lüftner, et al.. (2023). Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer. JAMA Network Open. 6(4). e235822–e235822.
5.
Ahn, Hee Kyung, Sung Hoon Sim, Koung Jin Suh, et al.. (2022). Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. JAMA Oncology. 8(9). 1271–1271.
6.
Lee, Young Joo, Sae Byul Lee, Guiyun Sohn, et al.. (2019). Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. Annals of Surgical Oncology. 26(7). 2166–2174.
7.
Park, Ji Hyun, Ji Sung Lee, Jeong Eun Kim, et al.. (2019). How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers. Journal of Cancer Education. 35(3). 545–556.
8.
Pivot, Xavier, Igor Bondarenko, Zbigniew Nowecki, et al.. (2018). A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. European Journal of Cancer. 93. 19–27.
9.
Pivot, Xavier, Igor Bondarenko, Zbigniew Nowecki, et al.. (2017). One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment. Annals of Oncology. 28. v45–v45.
10.
Pivot, Xavier, Igor Bondarenko, Mikhail Dvorkin, et al.. (2017). A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 509–509.
11.
Lee, Hee Jin, In Hye Song, In Ah Park, et al.. (2016). Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget. 7(21). 30119–30132.
12.
Park, Ji Hyun, Myung Joo Kang, Jin‐Hee Ahn, et al.. (2016). Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. Cancer Chemotherapy and Pharmacology. 78(4). 685–695.
13.
Lee, Hee Jin, Joo Young Kim, In Ah Park, et al.. (2015). Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. American Journal of Clinical Pathology. 144(2). 278–288.
14.
Lee, Hee Jin, Joo Young Kim, In Hye Song, et al.. (2015). High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 467(6). 701–709.
15.
Kim, Sung‐Bae, Jin‐Hee Ahn, Jeongeun Kim, & Kyung Hae Jung. (2015). A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. Molecular Therapy — Methods & Clinical Development. 2. 15031–15031.
16.
Lee, Hee Jin, Jeong-Ju Lee, In Hye Song, et al.. (2015). Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment. 151(3). 619–627.
17.
Yeo, Winnie, Kyung Hae Jung, Seock‐Ah Im, et al.. (2013). PR99 QUALITY OF LIFE (QOL) IN METASTATIC BREAST CANCER PATIENTS WITH MAINTENANCE PACLITAXEL PLUS GEMCITABINE (PG) CHEMOTHERAPY: RESULTS FROM PHASE III, MULTICENTER, RANDOMIZED TRIAL OF MAINTENANCE CHEMOTHERAPY VERSUS OBSERVATION (KCSG-BR07-02). The Breast. 22. S53–S53.
18.
Lee, Hee Jin, Jin Young Seo, Jin‐Hee Ahn, Sei Hyun Ahn, & Gyungyub Gong. (2013). Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. 16(1). 32–32.
19.
Dwyer‐Nield, Lori D., Bradley S. Barrett, Jin‐Hee Ahn, et al.. (2005). Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis. 26(7). 1196–1206.
20.
Chang, Heung Moon, Tae Won Kim, Min‐Hee Ryu, et al.. (2004). Hand‐Foot Syndrome in Patients Treated With Capecitabine‐Containing Combination Chemotherapy. The Journal of Clinical Pharmacology. 44(10). 1166–1172.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shan Xiong Breakdown of academic impact, for papers by Ioannis Zerdes Breakdown of academic impact, for papers by Frédérique Penault‐Llorca Breakdown of academic impact, for papers by Marye J. Boers‐Sonderen Breakdown of academic impact, for papers by Tomasz Sarosiek Breakdown of academic impact, for papers by William Waterfield Breakdown of academic impact, for papers by Vincenzo Rosario Iaffaioli Breakdown of academic impact, for papers by Seyran Yiğit Breakdown of academic impact, for papers by Dalin Li Breakdown of academic impact, for papers by Rita Ruijter